

Oversight of DEA SORS Impact on Access to Addiction Medication (Tonko)

On page 3, at the end of the section entitled “ILLICIT DRUGS AND SUBSTANCE USE AND MISUSE”, insert this language:

“The Committee will examine barriers to the timely availability of buprenorphine products to treat opioid use disorder, including the influence of the Drug Enforcement Administration's (DEA) Suspicious Order Reporting System (SORS) on controlled substance distributors' willingness to distribute sufficient quantities of buprenorphine to pharmacies in order for pharmacies to effectively meet medically determined treatment needs in their communities.”